title: Testosterone replacement therapy and the risk of prostate cancer.
abstract: Understanding the role of testosterone replacement therapy (TRT) in the development and progression of prostate cancer is an important concept in treating patients with symptoms of hypogonadism. This article revealed a small number of mostly retrospective, observational studies describing the use of TRT in the general population, in men with prostatic intraepithelial neoplasia (PIN), in men with a history of treated prostate cancer, and in men on active surveillance for prostate cancer. The current literature does not report a statistically significant increase in the development or progression of prostate cancer in men receiving testosterone replacement for symptomatic hypogonadism, and the prostate saturation theory provides a model explaining the basis for these results. The use of TRT in men with a history of prostate cancer is considered experimental, but future results from randomized controlled trials could lead to a change in our current treatment approach.
authors: Daniel
authors: D
authors: Warburton
authors: Christopher
authors: C
authors: Hobaugh
authors: Grace
authors: G
authors: Wang
authors: Haocheng
authors: H
authors: Lin
authors: Division of Urology, University of Texas Medical School at Houston, Department of Urology; University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors: Run
authors: R
authors: Wang
mesh_terms: D000728:Androgens / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D019048:Prostatic Intraepithelial Neoplasia / Q000453:epidemiology*; D011471:Prostatic Neoplasms / Q000453:epidemiology*; D012307:Risk Factors; D013739:Testosterone / Q000627:therapeutic use*
chemical_list: D000728:Androgens; D013739:Testosterone